Osteoprotegerin, RANKL, ADMA, and Fetuin-A serum levels in children with type I diabetes mellitus

被引:11
作者
Chrysis, Dionisios [1 ]
Efthymiadou, Alexandra [1 ]
Mermigka, Alexandra [2 ]
Kritikou, Dimitra [2 ]
Spiliotis, Bessie E. [1 ]
机构
[1] Univ Patras, Med Sch, Div Endocrinol, Dept Pediat, Patras, Greece
[2] Univ Patras, Med Sch, Dept Pediat, Patras, Greece
关键词
osteoprotegerin; ADMA; Fetuin-A; diabetes mellitus type 1; children; ASYMMETRIC DIMETHYLARGININE ADMA; CARDIOVASCULAR RISK-FACTORS; CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; ENDOTHELIAL DYSFUNCTION; KIDNEY-FUNCTION; MORTALITY; ATHEROSCLEROSIS; INSULIN; MORBIDITY;
D O I
10.1111/pedi.12384
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chrysis D, Efthymiadou A, Mermigka A, Kritikou D, Spiliotis BE. Osteoprotegerin, RANKL, ADMA, and Fetuin-A serum levels in children with type I diabetes mellitus. Pediatric Diabetes 2017: 18: 277-282. Introduction: Patients with type I diabetes mellitus (T1DM) have increased incidence of atherosclerosis and cardiovascular disease. Although these complications are unusual in children with T1DM, prevention, and early intervention could decrease morbidity and mortality. Osteoprotegerin (OPG), asymmetric dimethylarginine (ADMA), and Fetuin-A have been associated with increased cardiovascular risk (CVR). Increased OPG and ADMA, and decreased or increased Fetuin-A serum levels have been associated with increased CVR. Aim: Because patients with T1DM have higher CVR we investigated OPG, ADMA, and Fetuin-A, in children with T1DM. Methods: We determined the serum levels of OPG, receptor activator of nuclear factor-kappa B ligand (RANKL), ADMA, and Fetuin-A by enzyme-linked immunosorbent assay (ELISA) in 56 children with T1DM aged 12.1 +/- 3.4 yr and in 46 normal control children, (C) aged 11.3 +/- 3.0 yr. Results: Serum OPG levels were significantly increased in patients with T1DM (3.352 +/- 0.73 pmol/L) compared with C (2.75 +/- 0.67 pmol/L, p<0.0001) but RANKL did not change. ADMA was significantly decreased in T1DM compared with C (0.68 +/- 0.13 mu mol/L versus 0.82 +/- 0.18 mu mol/L, p<0.0001). Fetuin-A was similar in T1DM (0.551 +/- 0.13 g/L) and C (0.540 +/- 0.11 g/L) subjects. OPG was positively associated with glycosylated hemoglobin A1c (p<0.001) and negatively associated with BMI (p<0.01). ADMA and Fetuin-A were not associated with A1c and ADMA was only negatively associated with age (p<0.05). Conclusion: OPG is increased, ADMA is decreased, but RANKL and Fetuin-A are unchanged in T1DM children. Whereas increased OPG has been firmly related to increased CVR, more studies, especially longitudinal studies, are needed to delineate the role and clinical significance of decreased ADMA and if Fetuin-A has any role in T1DM.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 47 条
[1]   Evaluation of fetuin-A and carotid intima-media thickness in adolescent type 1 diabetic patients [J].
Abd El Dayem, Soha M. ;
Battah, Ahmed A. ;
El Bohy, Abo El Magd ;
El Shehaby, Amal .
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2015, 28 (3-4) :287-292
[2]   Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations [J].
Altinova, Alev E. ;
Arslan, Metin ;
Sepici-Dincel, Aylin ;
Akturk, Mujde ;
Altan, Nilgun ;
Toruner, Fusun B. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (05) :1881-1885
[3]   Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus [J].
Anderssohn, Maike ;
Schwedhelm, Edzard ;
Lueneburg, Nicole ;
Vasan, Ramachandran S. ;
Boeger, Rainer H. .
DIABETES & VASCULAR DISEASE RESEARCH, 2010, 7 (02) :105-118
[4]   Osteoprotegerin:: A novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients [J].
Avignon, Antoine ;
Sultan, Ariane ;
Piot, Christophe ;
Mariano-Goulart, Denis ;
Dieudonné, Jean-Francois Thuan dit ;
Cristol, Jean Paul ;
Dupuy, Anne Marie .
DIABETES CARE, 2007, 30 (11) :2934-2939
[5]   Asymmetric dimethylarginine (ADMA):: A novel risk factor for endothelial dysfunction -: Its role in hypercholesterolemia [J].
Böger, RH ;
Bode-Böger, SM ;
Szuba, A ;
Tsao, PS ;
Chan, JR ;
Tangphao, O ;
Blaschke, TF ;
Cooke, JP .
CIRCULATION, 1998, 98 (18) :1842-1847
[6]   Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women [J].
Browner, WS ;
Lui, LY ;
Cummings, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :631-637
[7]   Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature [J].
Dabrowska, Anna Maria ;
Tarach, Jerzy Stanislaw ;
Wojtysiak-Duma, Beata ;
Duma, Dariusz .
BIOMEDICAL PAPERS-OLOMOUC, 2015, 159 (03) :352-359
[8]   Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment? [J].
Dahl-Jorgensen, K ;
Larsen, J ;
Hanssen, K .
DIABETOLOGIA, 2005, 48 (08) :1445-1453
[9]   Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass [J].
Dimitri, P. ;
Wales, J. K. ;
Bishop, N. .
BONE, 2011, 48 (02) :189-196
[10]   Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status [J].
Galluzzi, F ;
Stagi, S ;
Salti, R ;
Toni, S ;
Piscitelli, E ;
Simonini, G ;
Falcini, F ;
Chiarelli, F .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (06) :879-885